Related Experiment Videos
[Treatment of atrial fibrillation: a persistent dilemma]
Insights
Atrial fibrillation (AF) management presents challenges, especially regarding stroke prevention in older adults. Oral anticoagulants are key, but balancing bleeding and clotting risks requires individualized treatment.
Area of Science:
- Cardiology
- Internal Medicine
- Geriatrics
Background:
- Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, with increasing prevalence due to longer life expectancy.
- Oral anticoagulant therapy is the established standard for preventing systemic embolism in AF patients.
- Treatment decisions for AF are complex, involving balancing stroke risk, bleeding risk, and rhythm control strategies.
Discussion:
- The incidence of systemic embolism in AF patients is influenced by underlying heart disease and advanced age.
- Older patients with AF face a higher risk of hemorrhage when undergoing oral anticoagulant therapy.
- Individualized oral anticoagulant therapy, carefully titrated to a safe and effective INR, is crucial for AF patients.
Key Insights:
- Identifying patients with paroxysmal AF who are at risk for systemic embolism remains a challenge.
- Advanced age, hypertension, and left atrial enlargement are significant risk factors for embolism in non-valvular paroxysmal AF.
- A history of embolism suggests AF may activate systemic coagulation, leading to left atrial thrombus formation.
Outlook:
- Ongoing multicenter trials are investigating the optimal approach to AF management, including rhythm control versus rate control.
- Further research is needed to refine risk stratification for systemic embolism in paroxysmal AF.
- Developing personalized treatment strategies that minimize both embolic and bleeding risks is essential for improving outcomes in AF patients.
Abstract:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Increased life expectancy will result in a higher prevalence of AF. Treatment of AF constitutes a persistent medical dilemma. Different multicenter trials have confirmed that oral anticoagulant therapy is the best choice for the prevention of systemic embolism. It must be recognized, however, that the incidence of systemic embolism in patients with AF varies according to the presence and type of underlying heart disease. Advanced age increases the risk of emboli in patients with AF. At the same time, older patients have a higher risk of hemorrhage when treated with oral anticoagulants. Thus, careful titrated individual oral anticoagulant therapy targeted to a safe and effective INR must be considered in patients with AF. Another dilemma in AF patients is the convenience of restoring sinus rhythm and indicating permanent antiarrhythmic therapy versus the alternative of heart rate control plus oral anticoagulants. Several multicenter trials now in progress have addressed this issue and most likely will answer these questions. Identification of patients with paroxysmal AF and risk of systemic embolism constitutes another dilemma, since only a small proportion of these patients evolve to chronic arrhythmia. Advanced age, history of hypertension and left atrial enlargement in 2D Echo are well recognized risk factors for embolism in patients with non valvular paroxysmal AF. A history of previous embolism constitutes another risk factor and supports the hypothesis that AF may activate systemic coagulation factors and left atrial thrombus formation in some patients.